Chimeric Proteins Targeting Non-Cellular Structures
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic agents often fail to effectively target non-cellular components of the tumor microenvironment, such as the extracellular matrix, which are crucial in cancer progression and metastasis, leading to inadequate treatment outcomes.
Innovation Solution
Development of chimeric proteins with targeting moieties that specifically bind to non-cellular structures like tenascin, fibronectin, and laminin, combined with modified signaling agents like interferons and tumor necrosis factors, to deliver therapeutic signals directly to the tumor microenvironment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapeutic agents are used, then treatment is administered, but they fail to effectively target non-cellular components of the tumor microenvironment
Solution Approach 1:
The therapeutic agent is divided into separate functional modules: a targeting moiety that specifically binds to non-cellular structures (ECM components like tenascin, fibronectin, laminin) and a signaling agent (cytokine or chemokine). This segmentation allows the targeting moiety to selectively anchor to non-cellular components while the signaling agent delivers therapeutic effects locally, thereby improving targeting effectiveness without limiting target scope
Solution Approach 2:
The chimeric protein combines multiple functions into a single molecule: targeting capability through the targeting moiety, signaling capability through the cytokine/chemokine, and potential recruitment of effector cells. This multi-functionality enables the agent to simultaneously achieve specific targeting of non-cellular structures while maintaining versatility in therapeutic mechanisms, resolving the contradiction between reliability and adaptability
2Reliability
If chimeric proteins with targeting moieties are developed, then specific binding to non-cellular structures is achieved, but the complexity of the therapeutic agent increases
Solution Approach 1:
The chimeric protein structure embeds the signaling agent within or adjacent to the targeting moiety, creating a nested architecture where the cytokine/chemokine is positioned to be released or activated only after binding to the non-cellular target. This nesting reduces the effective complexity by organizing multiple functions in a hierarchical manner, maintaining binding specificity while simplifying the overall structural organization
Solution Approach 2:
The targeting moiety acts as an intermediary that mediates between the therapeutic delivery system and the non-cellular target structures. By using this intermediate component, the complex signaling functions are decoupled from the targeting function, allowing each to be optimized independently while reducing the overall system complexity through functional separation
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These chimeric proteins achieve potent therapeutic effects with minimal side effects by selectively targeting and modulating non-cellular structures, recruiting effector cells, and delivering critical signals to the tumor site, thereby enhancing cancer treatment efficacy.
Implementation Method 1
chimeric proteins having at least one targeting moiety that specifically binds to a target (e.g., an antigen or receptor or non-proteinaceous molecule) that is part of a non-cellular structure
Data Source
AI summary
The present invention relates, in part, to chimeric proteins that bind a non-cellular structure and their use as therapeutic agents. The present invention further relates to pharmaceutical compositions comprising the chimeric proteins and their use in the treatment of various diseases.